Quick Answer
Rein Therapeutics, Inc. reported Diluted EPS of $1.96 per share (loss) for fiscal year 2025.
Rein Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.96 | +44.2% |
| 2024 | -$3.51 | -2.6% |
| 2023 | -$3.42 | +43.2% |
| 2022 | -$6.02 | -2.2% |
| 2021 | -$5.89 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | +22.2% | +25.0% |
| June 30, 2025 | -$0.28 | +37.8% | -12.0% |
| March 31, 2025 | -$0.25 | +70.9% | +7.4% |
| September 30, 2024 | -$0.27 | +32.5% | +40.0% |
| June 30, 2024 | -$0.45 | -15.4% | +47.7% |
| March 31, 2024 | -$0.86 | +18.1% | -115.0% |
| September 30, 2023 | -$0.40 | +71.4% | -2.6% |
| June 30, 2023 | -$0.39 | +77.8% | +62.9% |
- Rein Therapeutics, Inc. showed an increase of +44.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Rein Therapeutics, Inc.’s diluted eps has grown by 66.7% (from $5.89 per share (loss) to $1.96 per share (loss)).
- The most recent figure is from Rein Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: